KMITL Innovation Expo 2025 Logo

PRIVARY

PRIVARY

Abstract

The "PRIVARY" product is an innovative herbal jelly beverage designed to support weight management and promote health through the benefits of four Thai herbs: roselle, safflower, chrysanthemum, and bitter melon. These herbs are rich in active compounds such as flavonoids, beta-carotene, and anthocyanins, which help reduce blood lipids, prevent inflammation, and exhibit antioxidant properties. The product emphasizes convenience and caters to health-conscious consumers using advanced production techniques like Inverse and External Gelation to create spheres encapsulating key bioactive compounds. Additionally, the product aligns with sustainability goals by enhancing the value of Thai herbs and supporting local communities.

Objective

ปัจจุบันการควบคุมน้ำหนักและสุขภาพเป็นเรื่องที่สำคัญสำหรับหลายคนแต่บ่อยครั้งที่การเลือกกินของหวานหรือขนมทำให้เรารู้สึกว่ากำลังละเมิดแผนควบคุมน้ำหนักของเราและกลัวว่าจะอ้วนหรือมีปัญหาสุขภาพตามมา เพื่อตอบโจทย์นี้ เราจึงได้แรงบันดาลใจในการพัฒนาเครื่องดื่มสมุนไพรในรูปแบบเยลลี่ที่ไม่เพียงแต่มีสรรพคุณในการช่วยควบคุมน้ำหนักและลดความอ้วน แต่ยังช่วยทำให้ร่างกายมีสุขภาพดีขึ้นด้วย โดยไม่ต้องพึ่งผลิตภัณฑ์เสริมหรือยาลดน้ำหนักที่อาจมีผลข้างเคียงที่เป็นอันตราย โดยผลิตภัณฑ์ของเราจะไม่เป็นเพียงแค่เครื่องดื่มสมุนไพรธรรมดา แต่จะถูกพัฒนาให้อยู่ในรูปแบบเครื่องดื่มเยลลี่ที่มีเม็ดสเฟียร์เป็นองค์ประกอบในเครื่องดื่มเพื่อสร้างความเพลิดเพลินในการรับประทาน และสามารถทานได้ง่ายเหมือนกินขนมที่ชื่นชอบ

Other Innovations

The use of Houttuynia cordata Thunb and Piper retrofractum Vahl extracts to inhibit opportunistic infections in patient with atopic dermatitis

คณะวิทยาศาสตร์

The use of Houttuynia cordata Thunb and Piper retrofractum Vahl extracts to inhibit opportunistic infections in patient with atopic dermatitis

Atopic dermatitis patients are the second largest number among skin disease patients. There is no cure for atopic dermatitis, and it can only be treated to relieve symptoms, causing chronic disease. There is a chance that opportunistic infections will enter and cause more disease from the patient's wound, causing the patient to have complications from other infections. This study is interested in studying the reduction of the chance of opportunistic infections in patients with atopic dermatitis using natural extracts. The interest is in Plu Kaow and long pepper because there is data supporting the inhibition of microorganisms. The leaves of both plants are crudely extracted, soaked in 95% ethanol for 7 days, filtered with a Buchner filter, and the extracts are tested for phytochemicals to analyze phenolic components, flavonoids, tannins, anthocyanin, DPPH, and tested for antimicrobial properties. The experiments consisted of 5 types of gram-positive and gram-negative bacteria: E. coli, Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis. The researcher expects that this can be further developed and used to treat patients with atopic dermatitis.

Read more
il n'y a rien à faire

คณะสถาปัตยกรรม ศิลปะและการออกแบบ

il n'y a rien à faire

This artwork was created based on the universal concepts of global warming and post-apocalyptic world, which has caused disturbances and chaos in ecosystems, leading to the extinction of many living beings on Earth due to human actions. Repairing and restoring this world may therefore be a false hope, connected to my personal experience of losing loved ones and the sorrow from setting high hope, through the artistic process using Animation Art and Sound Art.

Read more
In Silico Drug Discovery of Emerging Immune Checkpoint TIGIT-Binding Compounds for Cancer Immunotherapy: Computational Screening, Docking Studies, and Molecular Dynamics Analysis

คณะวิทยาศาสตร์

In Silico Drug Discovery of Emerging Immune Checkpoint TIGIT-Binding Compounds for Cancer Immunotherapy: Computational Screening, Docking Studies, and Molecular Dynamics Analysis

Cancer remains a major global health challenge as the second-leading cause of human death worldwide. The traditional treatments for cancer beyond surgical resection include radiation and chemotherapy; however, these therapies can cause serious adverse side effects due to their high killing potency but low tumor selectivity. The FDA approved monoclonal antibodies (mAbs) that target TIGIT/PVR (T-cell immunoglobulin and ITIM domain/poliovirus receptor) which is an emerging immune checkpoint molecules has been developed; however, the clinical translation of immune checkpoint inhibitors based on antibodies is hampered due to immunogenicity, immunological-related side effects, and high costs, even though these mAbs show promising therapeutic efficacy in clinical trials. To overcome these bottlenecks, small-molecule inhibitors may offer advantages such as better oral bioavailability and tumor penetration compared to mAbs due to their smaller size. Here, we performed structure-based virtual screening of FDA-approved drug repertoires. The 100 screened candidates were further narrowed down to 10 compounds using molecular docking, with binding affinities ranging from -9.152 to -7.643 kcal/mol. These compounds were subsequently evaluated for their pharmacokinetic properties using ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis, which demonstrated favorable drug-like characteristics. The lead compounds will be further analyzed for conformational changes and binding stability against TIGIT through molecular dynamics (MD) simulations to ensure that no significant conformational changes occur in the protein structure. Collectively, this study represents the potential of computational methods and drug repurposing as effective strategies for drug discovery, facilitating the accelerated development of novel cancer treatments.

Read more